Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
Journal of Microbiology and Biotechnology · 2025
DOI: 10.4014/jmb.2503.03002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2025. Verfasst von So Jin Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea. Hauptthemen laut MEDLINE: Bufanolides, Wnt Signaling Pathway, Neoplastic Stem Cells, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sun Moon University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea.
- Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University, Asan 31460, Republic of Korea.
- Genome-Based BioIT Convergence Institute, Sun Moon University, Asan 31460, Republic of Korea.
Förderung
- Sun Moon University
Zitieren
APA
Park, S. J., & Jung, H. J. (2025). Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2503.03002
Vancouver
Park SJ, Jung HJ. Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway. Journal of Microbiology and Biotechnology. 2025. doi:10.4014/jmb.2503.03002
BibTeX
@article{Park2025,
author = {Park, So Jin and Jung, Hye Jin},
title = {Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.4014/jmb.2503.03002}
}
EUVIMED